FDA approves fruquintinib for refractory metastatic colorectal cancerNov 6Regulatory decisionfruquintinib
AstraZeneca completes AZD4144-itraconazole PK study; posts five trial records this weekNov 6Weekly roundup, 12 itemsanifrolumab-fniaAstraZenecaUpdated
Cardiff Oncology posts results for terminated onvansertib pancreatic cancer trialNov 4Trial updateCardiff Oncology
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Johns Hopkins-sponsored HCC trial of Nivolumab plus Relatlimab posts results, now not recruitingOct 29Weekly roundup, 2 itemsBristol Myers Squibbnavlimetostat
AstraZeneca completes balcinrenone/dapagliflozin PK study; posts two new observational trialsOct 23Weekly roundup, 12 itemsabemaciclibAstraZeneca
Lilly posts two DC-806 Phase 1 DDI results; registers three new Phase 3 trialsOct 22Weekly roundup, 11 itemscetuximabdulaglutide
Fred Hutchinson posts Phase II acalabrutinib results; AstraZeneca's AZD0780 LDL-C trial completesOct 16Weekly roundup, 11 itemsacalabrutinibAstraZenecaUpdated
CytomX reports Q2 2026 results, advances Varseta-M toward first registrational studyAug 6Quarterly updateCytomX Therapeutics
XBiotech posts results for XB2001 pancreatic cancer trial, over five years after registrationAug 4Trial updateXB2001XBiotech, Inc.
NuCana's NuTide:303 trial for NUC-3373 combos terminated; results posted with 19 enrolledJul 23Trial updatefosifloxuridine nafalbenamideNuCana plc